NCT00096915View on ClinicalTrials.gov

Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis

PHASE3CompletedINTERVENTIONAL

Enrollment

110

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions

Kidney DiseaseChronic Kidney Disease

Interventions

DRUG

Darbepoetin Alfa

"QM administration for 32 weeks, allowable doses:~15, 20, 30, 40, 50, 60, 80, 100, 150, 200, 300, 400, 500, 600 and 800 mcg"

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY

NCT00096915 - Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis | Biotech Hunter | Biotech Hunter